Hemang Jani highlights the stability of diagnostic stocks like Dr Lal PathLabs. He also talks about the midcap stocks’ stability and performance despite high debt. Metro Brands and VIP Industries have been underperforming despite a tourism boom. He cautions against Hyundai due to slow growth but sees potential in future market corrections.
